Research programme: viral haemorrhagic fever - Emergent Biosolutions

Drug Profile

Research programme: viral haemorrhagic fever - Emergent Biosolutions

Alternative Names: Viral haemorrhagic fever therapeutics- Emergent Biosolutions

Latest Information Update: 31 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mapp Biopharmaceutical
  • Developer Emergent BioSolutions
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Viral haemorrhagic fevers

Most Recent Events

  • 13 May 2017 Early research in Viral haemorrhagic fevers in USA (unspecified route)
  • 13 Feb 2017 Emergent Biosolutions receives grant from Biomedical Advanced Research and Development Authority for viral haemorrhagic fever therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top